Investor Presentation Q1-Q3 2020

104 Investor presentation First nine months of 2020 Novo Nordisk volume market shares in the three insulin segments Novo Nordisk® 60% USA long-acting insulin USA premix insulin USA fast-acting insulin tMU tMU tMU 100 80% 80 80% 80 100% CAGR volume1: 1.6% MI penetration²: 67.5% CAGR volume1: (6.9%) CAGR volume1: 2.2% MI penetration: 48.9% MI penetration: 84.2% 80 80% 60% 60 60 60% 60 60 00 40 40 20 20 0 40% 40 40 20% 20 40% 40 20% 20 40% 20% 0% 0 0% Aug Aug Aug 2020 2015 Segment volume 2020 -NovoRapid Ⓡ Ⓡ Fiasp NN combined 0% 0 Aug 2015 Aug Aug 2020 2015 Segment volume-Levemir Ⓡ Segment volume Ⓡ -TresibaⓇ Combined NovoLog Mix share 70/30 1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units Note: The USA trend data reflect changes to IQVIA data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, i.e. including human insulin Source: IQVIA monthly MAT, Aug 2020 volume figures NN: Novo Nordisk

View entire presentation